

Carlsbad, CA— June 22, 2010. Omscientia, Inc. is pleased to announce that the company has entered into a distribution agreement with Zenobia Therapeutics (La Jolla, CA) to offer the entire proprietary Zenobia Fragment Screening Library to labs commercially as a screening kit. Omscientia is excited to be offering the unique Fragment Screen, which was developed by the Zenobia Therapeutics research team lead by CEO, Vicki Nienaber, pioneer of the Fragment Screening Method.

Fragment-based lead discovery, first reported in the mid-1990, is a powerful drug discovery tool yielding more than 10 clinical candidates. Overall, these candidates have chemical properties more consistent with marketed drugs than candidates discovered by other methods in part because the starting points are low molecular weight. Fragment hits usually bind very efficiently and have been optimized to IND candidates in less than 2 years.

When developed by Zenobia, the criteria for this library were far more stringent than the commonly quoted "rule-of-three." Potencies for compounds with these properties typically range from 1-10,000 uM. Highly soluble (200mM in 100% DMSO), the library is suitable for screening with NMR, SPR and x-ray crystallography. There are 352 compounds in total which ship as dry films in 96 well plates. Compounds are pre-grouped into shape-diverse mixtures for crystallographic screens.

Omscientia and Zenobia Therapeutics are both excited about the new agreement and believe it will help make Fragment Screening more widely available to labs worldwide while also reducing the investment required to do fragment screening. The Fragment Library is available immediately as a kit that can be purchased by labs wishing to employ Fragment-Based Lead Discovery. For more information on the Zenobia Fragment Library please contact Omscientia or visit their website at [www.Omscientia.com](http://www.Omscientia.com).

#### **About Omscientia, Inc.**

Based in Carlsbad, CA, Omscientia, Inc. develops and distributes life science technologies globally. Omscientia provides their customers with the highest quality laboratory products and the most innovative technologies the global market has to offer. At Omscientia, the best customer service in the industry, excellent sales teams and superior technical support all combine to provide life science instrumentation, reagents and consumables which are more accessible and affordable than ordering direct from international companies.

Omscientia™ was founded by professionals who understand technology and the needs of running a lab. The founders are scientists and industry leaders who have a background in technology development, drug discovery, manufacturing and service. The team shares the belief that satisfying customers is the primary mission. For further information visit: [www.Omscientia.com](http://www.Omscientia.com).

#### **About Zenobia Therapeutics, Inc.**

Based in La Jolla, California, Zenobia Therapeutics was founded June 1, 2008 by Vicki Nienaber, Robert Meadows and a team of scientists with over 100 combined years of experience in structure-directed drug design and fragment-based lead discovery. Zenobia Therapeutics is focused on the strengths of fragment-based methods to find novel, drug-like compounds that will cross the blood-brain barrier. Through close collaboration with leading experts in the field of neurodegenerative and psychiatric diseases, they are developing inhibitors for newly identified targets that may be rapidly tested in cell and animal models.

Working with foundations, research institutes and government agencies, they are discovering targeted treatments for rare diseases such as Parkinson's and Huntington's for which there is no cure. Their cost effective approach produces clinical candidates without the significant investment required for large-scale high-throughput screening campaigns and the building of large organizations. For further information visit: [www.ZenobiaTherapeutics.com](http://www.ZenobiaTherapeutics.com)